Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer

BACKGROUND: Bevacizumab, a monoclonal antibody against soluble VEGFA, is an approved and commonly administered anti-angiogenic drug in patients with metastasized colorectal cancer (mCRC). The survival benefit of anti-VEGF therapy in mCRC patients is limited to a few months, and acquired resistance m...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Genome Med
Autors principals: Zhou, Qing, Perakis, Samantha O., Ulz, Peter, Mohan, Sumitra, Riedl, Jakob M., Talakic, Emina, Lax, Sigurd, Tötsch, Martin, Hoefler, Gerald, Bauernhofer, Thomas, Pichler, Martin, Gerger, Armin, Geigl, Jochen B., Heitzer, Ellen, Speicher, Michael R.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7036260/
https://ncbi.nlm.nih.gov/pubmed/32087735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-020-0719-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars